Clinical Trials
14 trialsNCT05063565 2026-06-01
ROWAN
Boston Scientific Corporation
Phase 2 Active not recruiting
NCT03093116 2026-05-27
TRIDENT-1
Turning Point Therapeutics, Inc.
Phase 1/2 Recruiting
NCT07377487 2026-05-22
INDIGO
Boston Scientific Corporation
Phase NA Recruiting
NCT04198766 2025-12-18
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Phase 1/2 Active not recruiting
NCT03037385 2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2 Completed
NCT05233098 2025-03-06
TheraSphere Post-Approval Study to Calculate the Radiation-absorbed Dose of Tc-99m MAA.
Boston Scientific Corporation
Completed
NCT02112656 2024-08-20
OPTIMA
Imunon
Phase 3 Completed
NCT05160168 2024-06-05
A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
Theseus Pharmaceuticals
Phase 1/2 Terminated
NCT02753127 2023-11-15
CanStem303C
Sumitomo Pharma America, Inc.
Phase 3 Completed
NCT02993731 2023-11-15
CanStem111P
Sumitomo Pharma America, Inc.
Phase 3 Completed
NCT02897778 2022-04-28
Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors
Syndax Pharmaceuticals
Phase 1 Completed
NCT02909452 2022-01-25
Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Syndax Pharmaceuticals
Phase 1 Completed
NCT00841191 2014-05-14
A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors
Centocor, Inc.
Phase 1/2 Completed
NCT01009593 2012-09-10
Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
Abbott
Phase 3 Terminated